Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EPO

Tackling biosimilars – how to handle the threat to Pharma brands

Strategy Consultant Mark Assenti outlines three key points for developing a strategy to tackle the threat to Pharma brands from biosimilars.

Blue Latitude Health

- PMLiVE

Study clears Pfizer’s Champix of serious risks

Smoking-cessation drug 'does not increase risk' of depression or heart attacks

- PMLiVE

India denies patent on Pfizer’s Xeljanz

Drug deemed not an invention because it is not more effective than original compound

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

- PMLiVE

FDA follows WHO lead on biosimilar naming

Proposes adding suffixes to distinguish biosimilar drug names

- PMLiVE

Pfizer starts Ibrance trials in early breast cancer

Hopes to encourage wider use of breakthrough drug

- PMLiVE

Pfizer posts positive Trumenba vaccine data

Results from two new trials support FDA decision for accelerated approval

- PMLiVE

Pfizer and Flynn accused of overcharging for epilepsy drug

UK watchdog investigating the firms over the millions of pounds spent on Epanutin

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

Novartis building

US ruling clears Novartis’ Zarxio but could delay other biosimilars

Federalcourt's complex ruling could have a wide-ranging impact

- PMLiVE

The evolving biosimilars market

Safety and efficacy doubts remain a challenge

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links